Celularity and Verséa Ophthalmics Announce Exclusive U.S. Commercialization Agreement to Distribute Biovance® and Biovance® 3l Ocular For Ophthalmic Applications
July 27 2023 - 9:00AM
Celularity Inc. (Nasdaq: CELU) (“Celularity”), a biotechnology
company developing placental-derived allogeneic cell therapies and
biomaterial products, and Verséa Ophthalmics, LLC (“Verséa
Ophthalmics”), a Tampa, FL-based company that focuses on providing
complete ocular point-of-care diagnostic and therapeutic
interventions, today announced that the companies have entered into
an exclusive U.S. commercialization agreement in which Verséa
Ophthalmics will distribute Celularity’s BIOVANCE® and BIOVANCE® 3L
Ocular products to support the treatment of ocular surface disease
and ocular surgical applications.
BIOVANCE® and BIOVANCE® 3L Ocular, which are single-layer and
three-layer (3L) allografts, respectively, are intended for use as
a biological membrane covering that provides an extracellular
matrix. BIOVANCE® 3L Ocular is acellular and consists of three
layers of an amniotic membrane that supports treatment of advanced
ocular surface disease. As a barrier membrane, BIOVANCE® 3L Ocular
is intended to protect the underlying tissue and preserve tissue
plane boundaries. Applications include corneal and
conjunctival-related injuries or defects such as corneal epithelial
defects, pterygium repair, fornix reconstruction, and other
procedures, all of which are significant opportunities, the
companies believe.
The global persistent corneal epithelial defect management
market is currently valued at $8.5 billion, and is expected to grow
at an 18 percent compound annual growth rate (CAGR) through 2033,
reaching a valuation of $44.49 billion, according to Future Market
Insights.
“We are excited to partner with Verséa Ophthalmics to distribute
our BIOVANCE® and BIOVANCE® 3L Ocular products in the U.S.,” said
Robert J. Hariri, M.D., Ph.D., Celularity’s CEO, Chairman and
Founder. “Verséa Ophthalmics has the channel expertise in eye care
necessary to reach physicians and to provide patients in need
access to our innovative biomaterial technology.”
“As a corneal specialist by training, I have witnessed the
transformative impact innovative tissue-based ocular therapeutic
interventions can have for patients both in the clinic and
surgically,” said Rob Sambursky, M.D., President, Verséa
Ophthalmics. “Our commercialization agreement with Celularity
allows us to offer a decellularized, ringless, advanced wound
healing option to drive forward innovation for ocular surface
diseases.”
Terms of the agreement are not disclosed.
About Verséa Ophthalmics, LLC
Verséa Ophthalmics, LLC is a division of Verséa Health, Inc., a
diversified life-science company committed to delivering
innovative, high-value diagnostic and therapeutic solutions to
improve health care quality and access. It is specialized in the
sale and distribution of innovative solutions for the diagnosis,
treatment, and management of ocular surface diseases and surgical
wound healing. To learn more, visit: www.versea.com/ophthalmics
About Celularity
Celularity Inc. (Nasdaq: CELU) headquartered in Florham Park,
N.J., is a biotechnology company leading the next evolution in
cellular and regenerative medicine by developing allogeneic
cryopreserved off-the-shelf placental-derived cell therapies,
including therapeutic programs using mesenchymal-like adherent
stromal cells (MLASCs), T-cells engineered with CAR (CAR T-cells),
and genetically modified and unmodified natural killer (NK) cells
targeting indications in autoimmune, infectious and degenerative
diseases, and cancer. Celularity also develops, manufactures and
commercializes innovative biomaterial products also derived from
the postpartum placenta. Celularity believes that by harnessing the
placenta’s unique biology and ready availability, it can develop
therapeutic solutions that address significant unmet global needs
for effective, accessible, and affordable therapies.
To learn more, visit www.celularity.com
Celularity Media Contact:Paul Graves, Chief
Communications OfficerCelularity Inc.paul.graves@celularity.com
Verséa Media ContactRahim K.
Hirji, R. Ph.Verséa Ophthalmics, LLCrahim@versea.com
Celularity (NASDAQ:CELU)
Historical Stock Chart
From Apr 2024 to May 2024
Celularity (NASDAQ:CELU)
Historical Stock Chart
From May 2023 to May 2024